Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Ravit Geva, Mark Voskoboynik, Amy M Beebe, Jennifer Gwo, Konstantin Dobrenkov, Elliot Chartash, Georgina V. Long | ||||||||||||
Title | First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. | ||||||||||||
|
|||||||||||||
URL | http://abstracts.asco.org/214/AbstView_214_219785.html | ||||||||||||
Abstract Text | J Clin Oncol 36, 2018 (suppl; abstr 3029) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-1248 | MK-1248 is a monoclonal antibody binds to and activates glucocorticoid-induced TNF receptor (GITR), resulting in activation of anti-tumor immunity (J Clin Oncol 36, 2018 (suppl; abstr 3029), PMID: 32809217). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|